Speciality chemicals is a Business where small percentage moves in Margin can shift a company's valuation significantly. After a difficult period of destocking and weak demand, Croda has been trying to prove that it can grow profits again through a mixture of self-help and a recovery in its core markets.

Croda International (LSE:CRDA), the FTSE 100 constituent best known for ingredients used in beauty, personal care, pharmaceuticals and crop protection, set out its latest progress in half-year results on 28 July 2026. Sales rose, margins widened and growth picked up in the second quarter, while cost savings from its transformation programme began to show through. Full-year guidance, however, was left unchanged.

Growth quickened as the half went on

Group sales for the six months were £880.5m, up from £855.8m a year earlier, with organic and constant currency growth of 4.6%. The more encouraging detail was the shape of that growth: sales rose by around 9% in the second quarter, and the company said the impact from the Middle East was limited.

Chief executive Steve Foots described it as "a good first half performance in line with our expectations with strong growth in Consumer Care". Adjusted operating profit rose 6.1% to £155.8m, and adjusted profit before tax increased 7.0% to £147.7m. Reported profit before tax rose faster, up 25.6% to £107.4m, reflecting lower charges than in the prior year.

Where the margin improvement is coming from

The adjusted Operating Margin widened to 17.7% from 17.2%, and the EBITDA margin rose to 23.6% from 23.2%. Those are modest steps, but they matter because they came with only mid-single-digit sales growth, which points to cost control and pricing rather than Volume alone.

The transformation programme is central to this. Croda delivered £18m of incremental savings in the first half and is targeting about £100m of efficiency benefits by 2028, along with roughly £50m of Working Capital improvements. Adjusted operating profit growth was driven by improved pricing and cost savings.

Adjusted Earnings Per Share rose 8.9% to 78.6p, while Basic Earnings Per Share climbed 29.0% to 56.5p. Free Cash Flow increased to £38.3m from £28.0m, and net Debt eased slightly to £577.9m, giving Leverage of 1.4 times compared with 1.5 times a year earlier. The Interim Dividend was held at 48.0p.

Consumer Care leads while Life Sciences waits

The divisional picture shows where Croda's recovery is strongest. Consumer Care grew by around 8%, with Beauty Actives up 19%, Beauty Care 4%, Home Care 9% and Fragrances and Flavours 8%. Beauty Actives are high-value ingredients used in skincare, and their performance suggests Demand from premium beauty brands has held up well.

Life Sciences was flat. Pharma grew 1%, Crop Protection fell 2% and Seed Enhancement rose 4%. This division, which includes drug delivery excipients and lipid systems used in vaccines and other therapies, has been one of the main sources of disappointment in recent years, and management expects improving profitability here to support margins. Industrial Specialties sales fell 2%.

Sales of new and protected products, a measure of Croda's innovation pipeline, rose 6.9%. That matters for a group whose long-term premium valuation has depended on selling differentiated ingredients rather than Commodity chemicals.

The backdrop helps explain why this split matters. Across the speciality chemicals sector, customers spent much of the past few years running down inventories after the pandemic-era rush to secure supplies, which hit volumes for ingredient makers. Beauty has recovered faster than most end markets, helped by resilient demand for premium skincare. Pharmaceutical and agricultural customers, by contrast, have been more cautious, and that divergence is now clearly visible in Croda's divisional numbers.

Why the market reaction was muted

Shares were flat in early trading on results day. Momentum and execution were encouraging, but the unchanged guidance and flat dividend left little obvious near-term catalyst, even though the guidance looks cautious given improving sales trends and ongoing cost cuts.

The risks still hanging over the recovery

Croda's guidance was given "despite the ongoing geopolitical and macro-economic uncertainty", and that uncertainty is real. Consumer Care is sensitive to spending on beauty and personal care, so a slowdown in consumer demand could stall the division that is currently doing most of the work.

Life Sciences faces its own challenges. US regulatory headwinds are affecting pharmaceutical demand, and the agrichemicals market remains volatile, with pressure on crop protection. Trade policy is another variable for a group that makes and sells ingredients around the world.

There is also execution risk in the transformation programme itself. Savings targets stretching to 2028 require sustained delivery, and cost cuts can only go so far if volumes do not recover more broadly. Finally, a flat dividend underlines that the board is still balancing Shareholder returns with Investment and Balance Sheet discipline.

What comes next for Croda

For the full year, Croda continues to expect Organic Sales growth within its 3% to 6% range and a further increase in the adjusted operating margin, driven by better profitability in Consumer Care and Life Sciences and the benefits of transformation. Whether second-quarter momentum is sustained will be an early test, and Croda has typically issued a third-quarter trading update in October.

Full-year results would normally follow in February, as they did this year. Investors will want to see the margin gains extend into the second half, progress towards the £100m efficiency target, and evidence that Life Sciences is returning to growth. Given that the guidance looks cautious, any sign that the company is trending towards the upper part of its range would also attract attention.

Conclusion

For Croda (LSE:CRDA), the first half showed a business steadily rebuilding its margins through cost savings, pricing and a strong performance in beauty ingredients, with growth accelerating in the second quarter. Yet flat Life Sciences sales, a held dividend and unchanged guidance explain why the reaction was restrained. The coming quarters should reveal whether the transformation programme can deliver a sustained earnings recovery rather than a one-half improvement.